CA2069162A1 - Use of nizatidine to treat reflux esophagitis - Google Patents

Use of nizatidine to treat reflux esophagitis

Info

Publication number
CA2069162A1
CA2069162A1 CA002069162A CA2069162A CA2069162A1 CA 2069162 A1 CA2069162 A1 CA 2069162A1 CA 002069162 A CA002069162 A CA 002069162A CA 2069162 A CA2069162 A CA 2069162A CA 2069162 A1 CA2069162 A1 CA 2069162A1
Authority
CA
Canada
Prior art keywords
nizatidine
heartburn
reflux esophagitis
placebo
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002069162A
Other languages
English (en)
French (fr)
Inventor
Michelle L. Cloud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2069162A1 publication Critical patent/CA2069162A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002069162A 1991-05-28 1992-05-21 Use of nizatidine to treat reflux esophagitis Abandoned CA2069162A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70614591A 1991-05-28 1991-05-28
US07/706,145 1991-05-28

Publications (1)

Publication Number Publication Date
CA2069162A1 true CA2069162A1 (en) 1992-11-29

Family

ID=24836392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069162A Abandoned CA2069162A1 (en) 1991-05-28 1992-05-21 Use of nizatidine to treat reflux esophagitis

Country Status (10)

Country Link
EP (1) EP0516345A1 (enExample)
JP (1) JPH05148142A (enExample)
KR (1) KR920021144A (enExample)
AU (1) AU1721892A (enExample)
CA (1) CA2069162A1 (enExample)
HU (1) HU9201751D0 (enExample)
MX (1) MX9202507A (enExample)
NO (1) NO922019L (enExample)
TW (1) TW202387B (enExample)
ZA (1) ZA923711B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP3354276B1 (en) * 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
EP2506836B1 (en) 2009-12-02 2018-02-14 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them

Also Published As

Publication number Publication date
HU9201751D0 (en) 1992-08-28
MX9202507A (es) 1992-11-01
NO922019L (no) 1992-11-30
EP0516345A1 (en) 1992-12-02
TW202387B (enExample) 1993-03-21
KR920021144A (ko) 1992-12-18
ZA923711B (en) 1993-11-22
JPH05148142A (ja) 1993-06-15
AU1721892A (en) 1992-12-03
NO922019D0 (no) 1992-05-22

Similar Documents

Publication Publication Date Title
Lam et al. Treatment of duodenal ulcer with antacid and sulpiride: a double-blind controlled study
US5854267A (en) Method for preventing heartburn
Graham et al. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis
Vantrappen et al. Effect of 15 (R)-15-methyl prostaglandin E2 (arbaprostil) on the healing of duodenal ulcer: a double-blind multicenter study
RU2159614C2 (ru) Высушенные замораживанием композиции ондансетрона и способ лечения млекопитающих
US5989588A (en) Methods and compositions for preventing and treating heartburn
EP0426479B1 (en) Use of a composition for the manufacture of a medicament for curing the symptoms of overindulgence
Kang et al. Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer: comparison of initial healing and recurrence after healing
Agrawal et al. Healing of benign gastric ulcer: a placebo-controlled comparison of two dosage regimens of misoprostol, a synthetic analog of prostaglandin E1
Tytgat et al. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis: A review of three large, double-blind, controlled trials
CA2069162A1 (en) Use of nizatidine to treat reflux esophagitis
Cloud et al. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.
KR20250090275A (ko) 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
Gunasekaran et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability
Dolby et al. A trial of cromoglycic acid in recurrent aphthous ulceration
Reynolds Famotidine therapy for active duodenal ulcers: a multivariate analysis of factors affecting early healing
Hedenström et al. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast‐dissolving tablets to fasting healthy volunteers
Armbrecht et al. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole—comparison of 24‐hour intragastric and oesophageal pH
Navert Treatment of gastric ulcer with enprostil
Carling et al. Sucralfate versus placebo in reflux esophagitis: a double-blind multicenter study
Morris et al. Antacids and peptic ulcer--a reappraisal.
Farup Compliance with anti‐ulcer medication during short‐term healing phase clinical trials
RU2101014C1 (ru) Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения
Hui et al. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment
Porro et al. A double-blind endoscopic study with De-Nol® tablets and cimetidine for duodenal ulcer

Legal Events

Date Code Title Description
FZDE Discontinued